All In MedTech

Device Trial Radar · NCT05946603

IS-002 Phase 2 Prostate Cancer Study

Phase 2 Multi-Center Randomized Controlled Feasibility Study of IS-002 in Subjects Undergoing Robotic-Assisted Radical Prostatectomy Using the da Vinci® Surgical System With Firefly® Fluorescence Imaging

Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Jun 16, 2023

Primary completion

May 21, 2024

Study completion May 23, 2025

Sponsor

Lead sponsor
Intuitive SurgicalPublic (ISRG)
Sponsor type
Industry
First posted
Jul 14, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
Male only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2 randomized controlled multi-center study of IS-002, in conjunction with near-infrared (NIR) fluorescence imaging, for identification of prostate cancer during robotic-assisted radical prostatectomy (RARP) with (extended) pelvic lymph node dissection ((e)PLND) using the da Vinci® X/Xi Surgical System with Firefly® Fluorescence Imaging.

Conditions

  • Prostate Cancer

Interventions

  • Administration of IS-002Drug

    Intravenous administration of IS-002 approximately 24 hours prior to surgery

  • Firefly fluorescent imagingDevice

    Near-infrared fluorescence imaging using Firefly technology will allow fluorescence imaging of IS-002

  • robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissectionProcedure

    Subject will undergo robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects with ≥1 positive surgical margins (PSMs) on final histopathologic assessment in the Intervention arm and the Control arm.Time frame: Within 3 months post-surgery
  2. The mean number of positive surgical margins (PSMs) on final histopathologic assessment in the Intervention arm and the Control arm.Time frame: Within 3 months post-surgery

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • UCSF

    San Francisco, California

  • Johns Hopkins

    Baltimore, Maryland

  • Mayo Clinic

    Rochester, Minnesota

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.